標(biāo)題: Titlebook: Estrogen Receptor and Breast Cancer; Celebrating the 60th Xiaoting Zhang Book 2019 Springer Nature Switzerland AG 2019 estrogen receptor.br [打印本頁] 作者: infection 時(shí)間: 2025-3-21 16:44
書目名稱Estrogen Receptor and Breast Cancer影響因子(影響力)
書目名稱Estrogen Receptor and Breast Cancer影響因子(影響力)學(xué)科排名
書目名稱Estrogen Receptor and Breast Cancer網(wǎng)絡(luò)公開度
書目名稱Estrogen Receptor and Breast Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Estrogen Receptor and Breast Cancer被引頻次
書目名稱Estrogen Receptor and Breast Cancer被引頻次學(xué)科排名
書目名稱Estrogen Receptor and Breast Cancer年度引用
書目名稱Estrogen Receptor and Breast Cancer年度引用學(xué)科排名
書目名稱Estrogen Receptor and Breast Cancer讀者反饋
書目名稱Estrogen Receptor and Breast Cancer讀者反饋學(xué)科排名
作者: MENT 時(shí)間: 2025-3-21 21:39
https://doi.org/10.1007/978-3-031-29624-6r recruitment and selectivity, translating to varying degrees of receptor modulation and downstream functional effects. Dissecting these conformational state fluctuations within the context of variable cofactor profiles in different tissues, PTM induction, and emergence of hormonal treatment-related作者: Infect 時(shí)間: 2025-3-22 04:26
Cultural and Creative Mural Spacesne resistance include alterations of ER coregulators and pioneer factors, and genetic aberrations of ER itself. Recent advances in our understanding of the mechanisms of endocrine resistance, mostly provided by large-scale sequencing studies, further establish the roles of epigenetic alterations, th作者: 流逝 時(shí)間: 2025-3-22 06:13 作者: 挖掘 時(shí)間: 2025-3-22 09:56
Book 2019e, transcriptome and its regulation of noncoding RNAs such as microRNAs and enhancer RNAs in breast cancer; development and clinical practices of the first targeted therapy Tamoxifen and other antiestrogens for breast cancer treatment; structural basis of ER and antiestrogen actions; molecular insig作者: 啤酒 時(shí)間: 2025-3-22 13:51
The Estrogen-Regulated Transcriptome: Rapid, Robust, Extensive, and Transient,athways, impacting transcriptional programs and clinical outcomes in breast cancer. This chapter reviews the key features of ERα-regulated transcription and the current technological advances that have allowed for the careful dissection of these mechanisms.作者: 啤酒 時(shí)間: 2025-3-22 19:36
Structural Insights into Estrogen Receptors and Antiestrogen Therapies,r recruitment and selectivity, translating to varying degrees of receptor modulation and downstream functional effects. Dissecting these conformational state fluctuations within the context of variable cofactor profiles in different tissues, PTM induction, and emergence of hormonal treatment-related作者: 同義聯(lián)想法 時(shí)間: 2025-3-22 23:00 作者: Thymus 時(shí)間: 2025-3-23 05:10
Endocrine Disrupting Chemicals and Breast Cancer: The Saga of Bisphenol A,ogen whose adverse health effects have attracted considerable attention by scientists, industry, regulatory agencies, and the public at large. The disparate positions on health hazards by BPA, which have been undertaken by the chemical and food industries, environmental advocacy groups, health organ作者: 半導(dǎo)體 時(shí)間: 2025-3-23 06:19
2196-9906 in breast cancer; development and clinical practices of the first targeted therapy Tamoxifen and other antiestrogens for breast cancer treatment; structural basis of ER and antiestrogen actions; molecular insig978-3-030-07593-4978-3-319-99350-8Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 沒有準(zhǔn)備 時(shí)間: 2025-3-23 11:09 作者: 討厭 時(shí)間: 2025-3-23 15:53 作者: 演繹 時(shí)間: 2025-3-23 21:10
Silviane Barbato,Rossana Beraldo0, and CARM1, and their assembly into active DNA-bound estrogen receptor/coactivator complexes for initiation and for the subsequent step of elongation. This review specifically emphasizes the structural interaction within the estrogen receptor (ER) coactivator complex.作者: resilience 時(shí)間: 2025-3-23 22:46 作者: 微不足道 時(shí)間: 2025-3-24 05:44 作者: 單片眼鏡 時(shí)間: 2025-3-24 09:45 作者: 初次登臺(tái) 時(shí)間: 2025-3-24 11:57 作者: RAGE 時(shí)間: 2025-3-24 17:51 作者: 不法行為 時(shí)間: 2025-3-24 19:18 作者: 拖債 時(shí)間: 2025-3-25 03:02 作者: eczema 時(shí)間: 2025-3-25 05:33
Cultural Understanding of Soilsen receptor activities to determine and evaluate the physiological responses, in reproductive/gonadal tissues, neuroendocrine actions, and obesity related to adipose tissue and bone as some examples, linked to that receptors’ functional domains and tissue specificity.作者: 印第安人 時(shí)間: 2025-3-25 11:22 作者: Agnosia 時(shí)間: 2025-3-25 13:12
Ethnicity (Not Race) and Belonging, the context of ligand specificity and antiestrogen therapies. Here, we review the cross talk between ERα and miRNAs and their involvement in breast cancer progression, as well as resistance to endocrine therapy. We also briefly discuss the interaction of miRNAs with estrogen-related receptors (ERRs) and ERβ in mediating breast tumorigenesis.作者: MELD 時(shí)間: 2025-3-25 16:35 作者: BABY 時(shí)間: 2025-3-25 22:30
Cultural and Creative Industries with a safe SERM but to prevent breast cancer at the same time. Raloxifene is the result with no increase in endometrial cancer incidence. There are now five FDA-approved SERMS available for use: tamoxifen, raloxifene, bazedoxifene, toremifene, and ospemifene. All have connections with discovery and basic research in Jordan’s laboratory.作者: 衰老 時(shí)間: 2025-3-26 04:03 作者: Carcinogenesis 時(shí)間: 2025-3-26 07:48
Physiological and Pathological Roles of Estrogen Receptor,en receptor activities to determine and evaluate the physiological responses, in reproductive/gonadal tissues, neuroendocrine actions, and obesity related to adipose tissue and bone as some examples, linked to that receptors’ functional domains and tissue specificity.作者: 蜿蜒而流 時(shí)間: 2025-3-26 10:13 作者: 休閑 時(shí)間: 2025-3-26 15:58
Estrogen Receptor Regulation of MicroRNAs in Breast Cancer, the context of ligand specificity and antiestrogen therapies. Here, we review the cross talk between ERα and miRNAs and their involvement in breast cancer progression, as well as resistance to endocrine therapy. We also briefly discuss the interaction of miRNAs with estrogen-related receptors (ERRs) and ERβ in mediating breast tumorigenesis.作者: Insatiable 時(shí)間: 2025-3-26 17:58 作者: 愛社交 時(shí)間: 2025-3-26 20:57
,A Novel Strategy to Improve Women’s Health: Selective Estrogen Receptor Modulators, with a safe SERM but to prevent breast cancer at the same time. Raloxifene is the result with no increase in endometrial cancer incidence. There are now five FDA-approved SERMS available for use: tamoxifen, raloxifene, bazedoxifene, toremifene, and ospemifene. All have connections with discovery and basic research in Jordan’s laboratory.作者: Cytology 時(shí)間: 2025-3-27 02:09
Emerging Therapeutic Approaches to Overcome Breast Cancer Endocrine Resistance, 1 (MED1) using small molecules, antibodies, and RNA nanotechnology. We will also provide future perspective for other potential novel therapeutic targets such as epigenetic modification, noncoding RNAs, immunotherapy, etc. and the expansion of therapeutic options in endocrine-resistant breast cancers.作者: PSA-velocity 時(shí)間: 2025-3-27 05:29
Estrogen Receptor and Breast Cancer: A Historical Perspective,estrogen and a few more decades when Elwood Jensen announced the discovery of estrogen receptor. His work led to our understanding of how hormones control target gene transcription via their receptors. Several laboratories made major contributions toward our understanding of hormone action. To date,作者: 詞匯 時(shí)間: 2025-3-27 12:12
Physiological and Pathological Roles of Estrogen Receptor,clear activities of two receptor protein isoforms, ERα and ERβ, and multiple cell signaling mechanisms, including non-genomic and genomic actions. Genomic actions involve either direct DNA binding or tethered gene regulation. We describe herein some of the physiological responses of estrogen occurri作者: syncope 時(shí)間: 2025-3-27 16:31
Estrogen Receptor-Mediated Gene Transcription and Cistrome,ype nuclear receptor that primarily functions as a transcription factor. In this chapter, we will first describe the conserved domain architecture of ER and its regulation through various modifications by diverse intracellular pathways. We will then discuss the history and most recent advancement in作者: Rotator-Cuff 時(shí)間: 2025-3-27 18:13 作者: inhibit 時(shí)間: 2025-3-27 23:21
The Estrogen-Regulated Transcriptome: Rapid, Robust, Extensive, and Transient,r estrogens, the hormone acts by stimulating the DNA binding and transcriptional activity of estrogen receptors (ERs), transcription factors which robustly and transiently regulate the expression of target genes. More broadly, estrogen signaling controls the ER cistrome, as well as the epigenome and作者: 知識(shí) 時(shí)間: 2025-3-28 05:32 作者: 叫喊 時(shí)間: 2025-3-28 08:50 作者: 窩轉(zhuǎn)脊椎動(dòng)物 時(shí)間: 2025-3-28 11:15 作者: 膽小懦夫 時(shí)間: 2025-3-28 17:07
Endocrine Therapy in Clinical Practice,se settings. ET targets the ER pathway by blocking the body’s ability to produce estrogen or by directly modulating the ER. Since the estrogens are produced by the ovaries in premenopausal women and by some other tissues such as fat and skin in both premenopausal and postmenopausal women, ET for pre作者: Preserve 時(shí)間: 2025-3-28 22:19 作者: verdict 時(shí)間: 2025-3-29 02:51 作者: Institution 時(shí)間: 2025-3-29 05:07
,Estrogen Receptor β and Breast Cancer,ent of endocrine-resistant and metastatic phenotypes indicates the complexity of the mechanisms that regulate hormone signaling in the disease. The discovery of ERβ and its functional characterization has improved our understanding about the mechanism of estrogen receptor action, the regulation of e作者: LASH 時(shí)間: 2025-3-29 09:11 作者: Altitude 時(shí)間: 2025-3-29 14:46 作者: 展覽 時(shí)間: 2025-3-29 19:37
978-3-030-07593-4Springer Nature Switzerland AG 2019作者: 矛盾 時(shí)間: 2025-3-29 20:40 作者: 努力趕上 時(shí)間: 2025-3-30 01:13 作者: 消瘦 時(shí)間: 2025-3-30 07:20 作者: Ballerina 時(shí)間: 2025-3-30 09:06
